Search
Daptomycin
go.drugbank.com/drugs/DB00080ApprovedInvestigational[A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]
Octreotide
go.drugbank.com/drugs/DB00104ApprovedInvestigationalOn June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly.
Clorazepic acid
go.drugbank.com/drugs/DB00628ApprovedIllicitIn September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation.
Doxorubicin
go.drugbank.com/drugs/DB00997ApprovedInvestigational[A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin
Products: DOXOLEM RU, DOXORUBICIN AU 2MG/ML 10MGTrofinetide
go.drugbank.com/drugs/DB06045Approved[A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive
Betaine
go.drugbank.com/drugs/DB06756ApprovedInvestigationalNutraceuticalThe FDA and EMA have approved the product Cystadane (betaine anhydrous, oral solution) for the treatment of homocystinuria,[L43105,L43115] and the EMA has approved the use of Amversio (betaine anhydrous
Tocopherol
go.drugbank.com/drugs/DB11251ApprovedInvestigational[A32436] It is currently under the list of substances generally recognized as safe (GRAS) in the FDA for the use of human consumption.[L2114] … They present strong antioxidant activities, and it is determined as the major form of vitamin E.
Categories: Vitamin E, tocopherol (vit E)Products: VITAMINA E VCASelinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigational[L10145] The FDA approved Selinexor in June 2019.
Samidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigational[A235638, A235643] Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™
Lurbinectedin
go.drugbank.com/drugs/DB12674ApprovedInvestigational[A214331] On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression